Butyrate also contributes to GLP-1 signaling by upregulating GLP-1 receptor expression, thereby helping to improve GLP-1-mediated beneficial effects in MASLD [43]. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.